These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. IgG4-related disease in the eye and ocular adnexa. Derzko-Dzulynsky L Curr Opin Ophthalmol; 2017 Nov; 28(6):617-622. PubMed ID: 28858963 [TBL] [Abstract][Full Text] [Related]
23. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation]. MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443 [No Abstract] [Full Text] [Related]
24. Idiopathic orbital inflammation and Graves ophthalmopathy. Bijlsma WR; Kalmann R Arch Ophthalmol; 2010 Jan; 128(1):131-2. PubMed ID: 20065231 [No Abstract] [Full Text] [Related]
25. Mesalamine derivatives in the treatment of Crohn's disease. Harrell LE; Hanauer SB Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540 [TBL] [Abstract][Full Text] [Related]
26. You're the flight surgeon. Crohn's disease. Hartwich SA Aviat Space Environ Med; 2004 Aug; 75(8):716-7. PubMed ID: 15328792 [No Abstract] [Full Text] [Related]
27. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease. Rutgeerts P Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451 [No Abstract] [Full Text] [Related]
28. Medical therapy to reduce postoperative Crohn's disease recurrence. Achkar JP; Hanauer SB Am J Gastroenterol; 2000 May; 95(5):1139-46. PubMed ID: 10811318 [TBL] [Abstract][Full Text] [Related]
29. Mesalazine as a maintenance treatment in Crohn's disease. Sutherland LR; Steinhart AH Gut; 1998 Jan; 42(1):143-4. PubMed ID: 9505902 [No Abstract] [Full Text] [Related]
30. Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease. Akobeng AK Am J Gastroenterol; 2011 Oct; 106(10):1857; author reply 1857-8. PubMed ID: 21979212 [No Abstract] [Full Text] [Related]
31. Pediatric orbital pseudotumour presenting as a painless orbital and periocular mass. Mulvihill A; Smith CR; Buncic JR Can J Ophthalmol; 2004 Feb; 39(1):77-9. PubMed ID: 15040619 [No Abstract] [Full Text] [Related]
35. The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form. Prantera C; Bellinvia S Dig Liver Dis; 2005 Feb; 37(2):135-6. PubMed ID: 15733528 [No Abstract] [Full Text] [Related]
36. Treatment of Crohn's disease at the turn of the century. Bickston SJ; Cominelli F N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110 [No Abstract] [Full Text] [Related]
37. A comparison of budesonide and mesalamine for active Crohn's disease. Lowry PW; Sandborn WJ Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523 [No Abstract] [Full Text] [Related]
38. Education and imaging. Gastrointestinal: gastric Crohn's disease. Tseng TC; Chang YT; Wong JM J Gastroenterol Hepatol; 2007 Oct; 22(10):1690. PubMed ID: 17845696 [No Abstract] [Full Text] [Related]
39. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions. Kamm MA Inflamm Bowel Dis; 2005 Jun; 11(6):616-7. PubMed ID: 15905712 [TBL] [Abstract][Full Text] [Related]
40. Pregnancy and breastfeeding in patients with Crohn's disease. Mottet C; Juillerat P; Pittet V; Gonvers JJ; Froehlich F; Vader JP; Michetti P; Felley C Digestion; 2007; 76(2):149-60. PubMed ID: 18239407 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]